Compare PCRX & UVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | UVE |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 925.9M |
| IPO Year | 2010 | 1996 |
| Metric | PCRX | UVE |
|---|---|---|
| Price | $22.00 | $35.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $35.33 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 739.7K | 159.4K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | ★ 2.18% |
| EPS Growth | 107.44 | ★ 214.43 |
| EPS | 0.16 | ★ 6.32 |
| Revenue | $541,533,000.00 | ★ $1,603,915,000.00 |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $9.71 | $2.88 |
| P/E Ratio | $142.97 | ★ $5.61 |
| Revenue Growth | ★ 26.04 | 5.48 |
| 52 Week Low | $18.80 | $20.32 |
| 52 Week High | $27.99 | $36.68 |
| Indicator | PCRX | UVE |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 62.23 |
| Support Level | $20.41 | $30.42 |
| Resistance Level | $23.82 | $35.62 |
| Average True Range (ATR) | 1.00 | 1.52 |
| MACD | -0.00 | 0.38 |
| Stochastic Oscillator | 43.41 | 76.01 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Universal Insurance Holdings Inc is a private personal residential homeowner insurance company. The company develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners' lines of business and performs substantially all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The company generates revenue from the collection of premiums, earned net interest and dividend income from the investment portfolio, the collection of reinsurance recoverable and financing fees. The company's primary insurance subsidiaries, (UPCIC) and (APPCIC) provide insurance for personal residential: homeowners, renters/tenants, condo unit owners, and other related coverages.